JP2003516148A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516148A5
JP2003516148A5 JP2001544321A JP2001544321A JP2003516148A5 JP 2003516148 A5 JP2003516148 A5 JP 2003516148A5 JP 2001544321 A JP2001544321 A JP 2001544321A JP 2001544321 A JP2001544321 A JP 2001544321A JP 2003516148 A5 JP2003516148 A5 JP 2003516148A5
Authority
JP
Japan
Prior art keywords
piv
antigenome
virus
genome
chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001544321A
Other languages
English (en)
Japanese (ja)
Other versions
JP4795597B2 (ja
JP2003516148A (ja
Filing date
Publication date
Priority claimed from US09/458,813 external-priority patent/US7314631B1/en
Priority claimed from US09/459,062 external-priority patent/US7250171B1/en
Application filed filed Critical
Priority claimed from PCT/US2000/033293 external-priority patent/WO2001042445A2/en
Publication of JP2003516148A publication Critical patent/JP2003516148A/ja
Publication of JP2003516148A5 publication Critical patent/JP2003516148A5/ja
Application granted granted Critical
Publication of JP4795597B2 publication Critical patent/JP4795597B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001544321A 1999-12-10 2000-12-08 パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用 Expired - Fee Related JP4795597B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US17019599P 1999-12-10 1999-12-10
US09/459,062 1999-12-10
US60/170,195 1999-12-10
US09/458,813 US7314631B1 (en) 1997-05-23 1999-12-10 Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
US09/458,813 1999-12-10
US09/459,062 US7250171B1 (en) 1997-05-23 1999-12-10 Construction and use of recombinant parainfluenza viruses expressing a chimeric glycoprotein
PCT/US2000/033293 WO2001042445A2 (en) 1999-12-10 2000-12-08 USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS

Publications (3)

Publication Number Publication Date
JP2003516148A JP2003516148A (ja) 2003-05-13
JP2003516148A5 true JP2003516148A5 (enExample) 2008-02-07
JP4795597B2 JP4795597B2 (ja) 2011-10-19

Family

ID=27389780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001544321A Expired - Fee Related JP4795597B2 (ja) 1999-12-10 2000-12-08 パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用

Country Status (8)

Country Link
EP (1) EP1179054A2 (enExample)
JP (1) JP4795597B2 (enExample)
CN (2) CN102766605A (enExample)
AU (1) AU785148B2 (enExample)
CA (1) CA2362685A1 (enExample)
IL (1) IL144831A0 (enExample)
MX (1) MXPA01008108A (enExample)
WO (1) WO2001042445A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6764685B1 (en) 2000-03-21 2004-07-20 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines
UA93981C2 (ru) 2001-01-19 2011-03-25 Вироновативе Б.B. Вирус, который вызывает заболевание дыхательных путей у чувствительных k этому млекопитающих
US8715922B2 (en) 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
EP1456398B1 (en) 2001-11-21 2011-05-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Recovery of recombinant human parainfluenza virus type 1 (hpivi) from cdna
CA2477235A1 (en) 2002-02-21 2003-09-04 Medimmune Vaccines, Inc. Recombinant parainfluenza virus expression systems and vaccines comprising heterologous antigens derived from metapneumovirus
CA2490283A1 (en) 2002-07-01 2004-01-08 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance
US7820181B2 (en) 2002-09-18 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Recovery of recombinant human parainfluenza virus type 2 (HPIV2) from cDNA and use of recombinant HPIV2 in immunogenic compositions and as vectors to elicit immune responses against PIV and other human pathogens
JP2007524372A (ja) 2003-02-28 2007-08-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 組換えヒトメタニューモウイルスおよびその使用
JP2007525178A (ja) 2003-04-25 2007-09-06 メッドイミューン バクシーンズ，インコーポレイティド メタニューモウイルス株、そのワクチン製剤における用途、抗原性配列の発現のためのベクターとしての用途、並びにウイルス増殖方法
KR100999316B1 (ko) 2003-06-09 2010-12-10 와이어쓰 엘엘씨 ｃＤＮＡ로부터의 비분절 네가티브 쇄 ＲＮＡ 바이러스의회수를 위한 개선된 방법
DE102005006388A1 (de) 2005-02-11 2006-08-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Replikationsdefiziente RNA-Viren als Impfstoffe
US8178659B2 (en) 2005-05-11 2012-05-15 Wayne State University Targets for the identification of antibiotics that are not susceptible to antibiotic resistance
US8293517B2 (en) 2005-05-11 2012-10-23 Wayne State University Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance in Pseudomonas aeruginosa
JP4905649B2 (ja) * 2006-03-08 2012-03-28 国立大学法人 長崎大学 魚用ワクチン、その製造方法、および魚類感染症の予防方法
JP4892296B2 (ja) * 2006-08-24 2012-03-07 川崎製薬株式会社 魚類のエドワジェラ症及び連鎖球菌症用ワクチン
US8362203B2 (en) 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CN104093422B (zh) * 2012-01-24 2018-02-23 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
EP4089167A1 (en) 2012-02-09 2022-11-16 Baylor College of Medicine Pepmixes to generate multiviral ctls with broad specificity
CN103773803A (zh) * 2014-01-23 2014-05-07 中国农业科学院特产研究所 表达猪o型口蹄疫病毒vp1蛋白的重组牛副流感病毒载体
EP3630173A1 (en) 2017-05-29 2020-04-08 The United States of America, as represented by the Secretary, Department of Health and Human Services Recombinant chimeric bovine/human parainfluenza virus 3 expressing rsv g and its use
MX2020013961A (es) * 2018-06-27 2021-03-09 Medicago Inc Mutantes de hemaglutinina del virus de la influenza.
US20210319849A1 (en) * 2018-08-28 2021-10-14 Koninklijke Philips N.V. Method for assessing genome alignment basis
JP7656331B2 (ja) * 2019-03-25 2025-04-03 ベイラー カレッジ オブ メディスン 複数の呼吸器ウイルス抗原に特異的なｔ細胞及びその作製方法及び治療での使用方法
CN113462656B (zh) * 2021-03-24 2022-09-30 兰州生物制品研究所有限责任公司 一种人三型副流感病毒冷适应温度敏感株及其应用
CN113999292B (zh) * 2021-10-27 2023-05-26 中国农业大学 靶向呼吸道病毒属病毒的多肽抑制剂
CA3257090A1 (en) 2022-05-25 2023-11-30 Max Planck Gesellschaft REDUCED VECTOR ANTIGENICITY VACCINE
TW202535439A (zh) 2023-11-17 2025-09-16 美商賽諾菲巴斯德公司 海藻糖疫苗調配物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9809456B1 (pt) * 1997-05-23 2011-06-28 molécula isolada de polinucleotìdeo, composição de célula ou isenta de célula, partìcula de piv infeciosa, atenuada e imunogênica, e, composição imunogênica.
KR100940776B1 (ko) * 1999-07-09 2010-02-11 더 가버먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 리프리젠티드 바이 더 디파트먼트 오브 헬스 앤 휴먼 서비씨즈 약독화된 사람-소 키메라 파라인플루엔자바이러스(ｐｉｖ) 백신

Similar Documents

Publication Publication Date Title
JP2003516148A5 (enExample)
Collins et al. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics
Jin et al. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo
Liniger et al. Use of viral vectors for the development of vaccines
JP4795597B2 (ja) パラインフルエンザウィルス（ｐｉｖ）及びヒトの病原体により引き起こされる感染及び疾病を保護するためへの組換えｐｉｖのベクターとしての使用
US11028409B2 (en) Replication-deficient RNA viruses as vaccines
Radecke et al. Reverse genetics meets the nonsegmented negative-strand RNA viruses
KR100905450B1 (ko) 약독화된 인간-소 키메릭 호흡기 신시티움 바이러스백신의 제조 방법
JP2007097600A (ja) クローン化されたヌクレオチド配列からの感染性ＲＳウイルス（ｒｅｓｐｉｒａｔｏｒｙｓｙｎｃｙｔｉａｌｖｉｒｕｓ）の生産
JP2003504064A5 (enExample)
EP1194564B1 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines
EP1629004B1 (en) Immunogenic compositions comprising venezuelan equine encephalitis virus replicon vectors and paramyxovirus protein antigens
Skiadopoulos et al. Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes
CN105378090A (zh) 呼吸道合胞病毒半活疫苗
WO2012085936A2 (en) Recombinant respiratory syncytial virus plasmids and vaccines
JP2004515218A5 (enExample)
US7201907B1 (en) Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US7314631B1 (en) Use of recombinant live-attenuated parainfluenza virus (PIV) as a vector to protect against disease caused by PIV and respiratory syncytial virus (RSV)
JP2008537683A5 (enExample)
US20060099226A1 (en) Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
WO2001092548A2 (en) Vaccine and gene therapy vector and methods of use thereof
EP2152863B1 (en) Human parainfluenza viruses having separated p and c genes
Wiegand et al. Genome Replication-Incompetent Sendai Virus Vaccine Vector Against Respiratory Viral Infections That Is Capable of Eliciting a Broad Spectrum of Specific Immune Response
JPWO2021248086A5 (enExample)
HK1118297B (en) Replication-deficient rna viruses as vaccines